articleTop 1% cited
An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration
American Journal of Ophthalmology · 2007 · Vol. 143(4) · pp. 566–583.e2
Anne E. Fung(California Pacific Medical Center)Geeta A. Lalwani(University of Miami)Philip J. Rosenfeld✉(University of Miami)Sander R. Dubovy(University of Miami)Stephan MichelsWilliam J. Feuer(University of Miami)Carmen A. Puliafito(University of Miami)Janet L. Davis(University of Miami)Harry W. Flynn(University of Miami)Maria Esquiabro(University of Miami)
Retinal Diseases and TreatmentsRetinal Imaging and AnalysisRetinal and Optic ConditionsRanibizumabMedicineMacular degenerationVisual acuityOphthalmologyChoroidal neovascularizationRetinalRegimenOptical coherence tomographyDosing
MeSH terms
RanibizumabAgedAged, 80 and overAntibodies, MonoclonalFemaleFluorescein AngiographyHumansInjectionsMacular DegenerationMaleProspective StudiesVisual AcuityVitreous BodyTreatment OutcomeRetreatment
Citations
969
FWCI
76.62
field-weighted impact
References
9
Percentile
100%
vs. same field & year
Citations per year
Cited by
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
British Journal of Ophthalmology · 2014 · 633 citations
Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
American Journal of Ophthalmology · 2008 · 860 citations
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
American Journal of Ophthalmology · 2009 · 882 citations
References
Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin
Archives of Ophthalmology · 1999 · 2,186 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.